New Paper Alert
Diego Díaz García: AENEAS2 Explores Treatment Sequencing in EGFR-Mutated NSCLC
Diego Díaz-García/X

Diego Díaz García: AENEAS2 Explores Treatment Sequencing in EGFR-Mutated NSCLC

Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, shared on X:

“AENEAS2: aumolertinib + chemotherapy in EGFR+ NSCLC – The combination improved PFS vs aumolertinib alone:

  • PFS: 28.9 vs 18.9 months
  • HR 0.47; 95% CI 0.37-0.60; P<0.0001
  • G3-4 Neutropenia: 55% vs 1%

Significant benefit in PFS, with greater hematological toxicity. OS pending follow-up.”

Diego Díaz García

Title: Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial

Authors: Ziming Li, Jie Hu, Jianhua Chen, Yan Yu, Xiangjiao Meng, Xiaorong Dong, Yanping Hu, Yinghua Ji, Haifeng Liu, Weibo Wang, Fangling Ning, Zhihong Zhang, Chunling Liu, Zhiye Zhang, Qiming Wang, Wei Zheng, Honghai Wang, Xiujuan Qu, Zhenming Chen, Shaonan Fan, Xiaoqing Zhangu, Shun Lu.

Read the full article.

You can also read:

Hong Kong Model Finds EGFR/ALK-First Testing More Cost-Efficient Than Upfront NGS in Metastatic NSCLC

Diego Díaz García: AENEAS2 Explores Treatment Sequencing in EGFR-Mutated NSCLC

AENEAS2 Aumolertinib cancer Chunling Liu Diego Díaz García EGFR Fangling Ning Haifeng Liu Honghai Wang Jianhua Chen Jie Hu Lung cancer non small cell lung cancer NSCLC OncoDaily Oncology Qiming Wang Shaonan Fan Shun Lu Wei Zheng Weibo Wang Xiangjiao Meng Xiaoqing Zhangu Xiaorong Dong Xiujuan Qu Yan Yu Yanping Hu Yinghua Ji Zhenming Chen Zhihong Zhang Zhiye Zhang Ziming Li